Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - A KIMS database analysis

Roger Abs, Ulla Feldt-Rasmussen, Anders F. Mattsson, John P. Monson, Bengt Åke Bengtsson, M. Góth, Patrick Wilton, Maria Koltowska-Häggström

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Objective: The aim of the present study was to clarify the relationship between GH deficiency (GHD) and some cardiovascular risk factors and to analyse the effect of GH replacement therapy in a large number of patients over a prolonged period of time. Design: Data for analysis wer e retrieved from KIMS (Pfizer International Metabolic Database). Serum concentrations of total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides were obtained from 2589 patients at baseline and from 1206 patients after 1 and 2 years of GH replacement therapy. Body mass index (BMI), waist and hip, resting blood pressure and body composition were also measured. Results: At baseline, the unfavourable effects of GHD were most obvious in the lipid profile demonstrating elevated mean total and LDL-cholesterol, in the increased waist circumference and the elevated BMI. The cholesterol concentration, BMI and body composition were significantly adversely affected by a number of factors, including age, sex and the use of anti-epileptic drugs. The therapeutic effect of GH was essentially uniform across the whole population. GH replacement reduced significantly the mean total and LDL-cholesterol, the waist circumference and the fat mass and was maintained during 2 years. Conclusions: This analysis of a large number of patients confirmed that GHD adults present with an increased cardiovascular risk. The sustained improvement of the adverse lipid profile and body composition suggests that GH replacement therapy may reduce the risk of cardiovascular disease and the premature mortality seen in hypopituitary patients with untreated GHD.

Original languageEnglish
Pages (from-to)79-90
Number of pages12
JournalEuropean Journal of Endocrinology
Volume155
Issue number1
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Databases
Body Composition
LDL Cholesterol
Body Mass Index
Waist Circumference
Cholesterol
Lipids
Premature Mortality
Age Factors
Therapeutic Uses
HDL Cholesterol
Statistical Factor Analysis
Hip
Cardiovascular Diseases
Therapeutics
Fats
Blood Pressure
Serum
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Endocrinology

Cite this

Abs, R., Feldt-Rasmussen, U., Mattsson, A. F., Monson, J. P., Bengtsson, B. Å., Góth, M., ... Koltowska-Häggström, M. (2006). Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - A KIMS database analysis. European Journal of Endocrinology, 155(1), 79-90. https://doi.org/10.1530/eje.1.02179

Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - A KIMS database analysis. / Abs, Roger; Feldt-Rasmussen, Ulla; Mattsson, Anders F.; Monson, John P.; Bengtsson, Bengt Åke; Góth, M.; Wilton, Patrick; Koltowska-Häggström, Maria.

In: European Journal of Endocrinology, Vol. 155, No. 1, 07.2006, p. 79-90.

Research output: Contribution to journalArticle

Abs, R, Feldt-Rasmussen, U, Mattsson, AF, Monson, JP, Bengtsson, BÅ, Góth, M, Wilton, P & Koltowska-Häggström, M 2006, 'Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - A KIMS database analysis', European Journal of Endocrinology, vol. 155, no. 1, pp. 79-90. https://doi.org/10.1530/eje.1.02179
Abs, Roger ; Feldt-Rasmussen, Ulla ; Mattsson, Anders F. ; Monson, John P. ; Bengtsson, Bengt Åke ; Góth, M. ; Wilton, Patrick ; Koltowska-Häggström, Maria. / Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - A KIMS database analysis. In: European Journal of Endocrinology. 2006 ; Vol. 155, No. 1. pp. 79-90.
@article{9ae38df6cd30431aaba859209b71e52c,
title = "Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - A KIMS database analysis",
abstract = "Objective: The aim of the present study was to clarify the relationship between GH deficiency (GHD) and some cardiovascular risk factors and to analyse the effect of GH replacement therapy in a large number of patients over a prolonged period of time. Design: Data for analysis wer e retrieved from KIMS (Pfizer International Metabolic Database). Serum concentrations of total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides were obtained from 2589 patients at baseline and from 1206 patients after 1 and 2 years of GH replacement therapy. Body mass index (BMI), waist and hip, resting blood pressure and body composition were also measured. Results: At baseline, the unfavourable effects of GHD were most obvious in the lipid profile demonstrating elevated mean total and LDL-cholesterol, in the increased waist circumference and the elevated BMI. The cholesterol concentration, BMI and body composition were significantly adversely affected by a number of factors, including age, sex and the use of anti-epileptic drugs. The therapeutic effect of GH was essentially uniform across the whole population. GH replacement reduced significantly the mean total and LDL-cholesterol, the waist circumference and the fat mass and was maintained during 2 years. Conclusions: This analysis of a large number of patients confirmed that GHD adults present with an increased cardiovascular risk. The sustained improvement of the adverse lipid profile and body composition suggests that GH replacement therapy may reduce the risk of cardiovascular disease and the premature mortality seen in hypopituitary patients with untreated GHD.",
author = "Roger Abs and Ulla Feldt-Rasmussen and Mattsson, {Anders F.} and Monson, {John P.} and Bengtsson, {Bengt {\AA}ke} and M. G{\'o}th and Patrick Wilton and Maria Koltowska-H{\"a}ggstr{\"o}m",
year = "2006",
month = "7",
doi = "10.1530/eje.1.02179",
language = "English",
volume = "155",
pages = "79--90",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - A KIMS database analysis

AU - Abs, Roger

AU - Feldt-Rasmussen, Ulla

AU - Mattsson, Anders F.

AU - Monson, John P.

AU - Bengtsson, Bengt Åke

AU - Góth, M.

AU - Wilton, Patrick

AU - Koltowska-Häggström, Maria

PY - 2006/7

Y1 - 2006/7

N2 - Objective: The aim of the present study was to clarify the relationship between GH deficiency (GHD) and some cardiovascular risk factors and to analyse the effect of GH replacement therapy in a large number of patients over a prolonged period of time. Design: Data for analysis wer e retrieved from KIMS (Pfizer International Metabolic Database). Serum concentrations of total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides were obtained from 2589 patients at baseline and from 1206 patients after 1 and 2 years of GH replacement therapy. Body mass index (BMI), waist and hip, resting blood pressure and body composition were also measured. Results: At baseline, the unfavourable effects of GHD were most obvious in the lipid profile demonstrating elevated mean total and LDL-cholesterol, in the increased waist circumference and the elevated BMI. The cholesterol concentration, BMI and body composition were significantly adversely affected by a number of factors, including age, sex and the use of anti-epileptic drugs. The therapeutic effect of GH was essentially uniform across the whole population. GH replacement reduced significantly the mean total and LDL-cholesterol, the waist circumference and the fat mass and was maintained during 2 years. Conclusions: This analysis of a large number of patients confirmed that GHD adults present with an increased cardiovascular risk. The sustained improvement of the adverse lipid profile and body composition suggests that GH replacement therapy may reduce the risk of cardiovascular disease and the premature mortality seen in hypopituitary patients with untreated GHD.

AB - Objective: The aim of the present study was to clarify the relationship between GH deficiency (GHD) and some cardiovascular risk factors and to analyse the effect of GH replacement therapy in a large number of patients over a prolonged period of time. Design: Data for analysis wer e retrieved from KIMS (Pfizer International Metabolic Database). Serum concentrations of total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides were obtained from 2589 patients at baseline and from 1206 patients after 1 and 2 years of GH replacement therapy. Body mass index (BMI), waist and hip, resting blood pressure and body composition were also measured. Results: At baseline, the unfavourable effects of GHD were most obvious in the lipid profile demonstrating elevated mean total and LDL-cholesterol, in the increased waist circumference and the elevated BMI. The cholesterol concentration, BMI and body composition were significantly adversely affected by a number of factors, including age, sex and the use of anti-epileptic drugs. The therapeutic effect of GH was essentially uniform across the whole population. GH replacement reduced significantly the mean total and LDL-cholesterol, the waist circumference and the fat mass and was maintained during 2 years. Conclusions: This analysis of a large number of patients confirmed that GHD adults present with an increased cardiovascular risk. The sustained improvement of the adverse lipid profile and body composition suggests that GH replacement therapy may reduce the risk of cardiovascular disease and the premature mortality seen in hypopituitary patients with untreated GHD.

UR - http://www.scopus.com/inward/record.url?scp=33746370734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746370734&partnerID=8YFLogxK

U2 - 10.1530/eje.1.02179

DO - 10.1530/eje.1.02179

M3 - Article

C2 - 16793953

AN - SCOPUS:33746370734

VL - 155

SP - 79

EP - 90

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -